Our company is oriented to meet clinical needs and is committed to hepatitis B, cancer, the development of innovative medicines and improved new medicines in areas such as severe infections and gynecology. According to the latest national drug registration classification principle, In our R&D pipeline, There are Classes 1 of First in Class/Best in Class; and also exclusive patented products for fixed-dose combinations. There are also new formulations that are more suitable for clinical applications, or "improved innovations" that change salt, or new clinical uses. The product layout is reasonable and thereliable!
Copyright:2018-2025 All rights reserved Nanjing Gritpharma Co .,Ltd 苏ICP备15048906号 Power:www.300.cn
Add：5th Floor, Building 9, Nanjing Life Science and Technology Innovation Town, No. 568 Longmian Avenue, Jiangning District, Nanjing, Jiangsu, China
Innovation and research